Medytox Q2 Revenue Rises 11.4% as Filler Sales Grow
Medytox posted second-quarter revenue of KRW 68.7 billion, up 11.4% from a year earlier, on growth in its domestic and overseas toxin and filler businesses.
This article was automatically drafted and passed editorial compliance checks. It synthesizes public source metadata and is not a substitute for individual care or clinical review.
Medytox posted consolidated second-quarter revenue of KRW 68.7 billion, up 11.4% from a year earlier. Expanded sales of toxins, fillers and new products carried the increase.
Growth in the domestic and overseas toxin and filler businesses, together with the fat-reduction injectable Newbijou establishing itself in the Korean market, lifted revenue, and toxin products held a steady sales trend at home and abroad.
What the earnings reports showed
Consolidated operating profit for the quarter was KRW 4.8 billion and net profit KRW 3.1 billion. Against the same period a year earlier, operating profit fell 24.6% and net profit 61.7%.
Higher costs from business expansion weighed on those profits. Filler and toxin growth pushed revenue up while profitability came down in the same quarter.
Limits and patient context
These are company earnings and product sales figures, not evidence about the effectiveness, side effects, recovery, or patient outcomes of any particular filler. Revenue growth reads as a business result, not as guidance for choosing a treatment.
Anyone considering filler treatment should account for individual variation and consult a qualified physician about the specific product, the expected effect, possible side effects, and recovery considerations. Company earnings figures cannot replace an individualized clinical assessment.
Questions for a consultation
At the consultation, ask which filler is proposed and why it suits the intended treatment area. Keep company-level sales growth and product-specific information separate.
Ask as well how individual variation is assessed, which side effects warrant attention, and what recovery guidance applies. These are treatment questions beyond a quarterly result and belong in a clinical consultation.
Frequently asked questions
How much was Medytox's second-quarter revenue?
Consolidated second-quarter revenue was KRW 68.7 billion, up 11.4% year over year. Growth in the domestic and overseas toxin and filler businesses contributed to the increase.
Why did Medytox's profits decline while revenue grew?
Higher costs related to business expansion affected profitability. Operating profit fell 24.6% and net profit fell 61.7% from a year earlier.
Does higher filler sales growth show how a filler will work for me?
No. Both reports covered company sales and earnings, not individual treatment effectiveness, side effects, recovery, or outcomes; consult a qualified physician for an assessment that accounts for individual variation.
Filler consultation checklist
- Which filler are you proposing, and why is it appropriate for the treatment area?
- How could individual variation affect the expected result in my case?
- Which possible side effects should I watch for, and when should I seek help?
- What recovery guidance applies to the proposed treatment?
- What product-specific information supports this recommendation?
MediIndex articles are for general information only and are not medical advice, diagnosis, or advertising. Outcomes vary by individual — consult a board-certified specialist for personal decisions.
